Literature DB >> 8590852

Leukemic transformation of primary myelofibrosis: immunophenotype, genotype and growth characteristics of blast cells.

A Kimura1, K Kawaishi, Y Nakata, H Hyodo, A Kuramoto, Y Satow.   

Abstract

Blast cells from six patients with leukemic transformation of primary myelofibrosis (PMF) were studied by morphology, immunophenotype and genotype as well as response to hematopoietic growth factors. The majority of the patients showed granulocytic or granulo-monocytic blasts, and only one had T lymphoid-monocytic blasts. None of the patients showed rearrangement of Ig or TCR genes, or the existence of the bcr-abl fused gene. A prominent growth response to GM-CSF and IL-3 was evident in all of the patients examined in liquid as well as semisolid cultures. The response to G-CSF was observed in four of the six patients in suspension culture, and in two of three patients in the clonogenic assay. Stem cell factor (SCF) was a weak growth stimulant, however the combination of this factor with GM-CSF or IL-3 was synergistically stimulatory. These results suggest that leukemic transformation of PMF occurs mainly at the level of myeloid stem cell, and that GM-CSF, IL-3, G-CSF and SCF are major growth factors for the blast cells in these cases.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8590852     DOI: 10.3109/10428199509112210

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  2 in total

Review 1.  Myeloid blastic transformation of myeloproliferative neoplasms--a review of 112 cases.

Authors:  Syed J Noor; Wei Tan; Gregory E Wilding; Laurie A Ford; Maurice Barcos; Sheila N J Sait; Annemarie W Block; James E Thompson; Eunice S Wang; Meir Wetzler
Journal:  Leuk Res       Date:  2010-08-19       Impact factor: 3.156

2.  Primary myelofibrosis terminated in basophilic leukemia and successful allogeneic bone marrow transplantation.

Authors:  Naoshi Sugimoto; Takayuki Ishikawa; Saori Gotoh; Isaku Shinzato; Akiko Matsushita; Kenichi Nagai; Noriko Ohgoh; Takayuki Takahashi
Journal:  Int J Hematol       Date:  2004-08       Impact factor: 2.490

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.